Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius    FRE   DE0005785604

FRESENIUS

(FRE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius : makes solid start to 2019 and confirms Group guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/02/2019 | 01:33am EDT
  • Contact

    Matthias Link

    Vice President Corporate Communications
    T: +49 (0) 6172 608-2872
    matthias.link@fresenius.com

  • Documents

You will find the full text of the message here shortly. Until then, you can download the press release as a PDF file.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Disclaimer

Fresenius SE & Co. KGaA published this content on 02 May 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 02 May 2019 05:32:04 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS
06/21FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
06/14FRESENIUS : Medical Care successfully places USD bonds
PU
06/12FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
06/11FRESENIUS : Kabi Introduces Neostigmine Methylsulfate Injection, USP Simplist Pr..
AQ
06/06Will Europe's clampdown on faulty medical devices hurt patients?
RE
06/03FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
05/31FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the Germa..
EQ
05/20FRESENIUS : Ex-dividend day for final dividend
FA
05/17ANNUAL GENERAL MEETING : Fresenius on course for continued growth, 26th straight..
PU
05/16FRESENIUS : Medical Care stays on course for growth – Annual General Meeti..
PU
More news
Financials (€)
Sales 2019 35 296 M
EBIT 2019 4 698 M
Net income 2019 1 887 M
Debt 2019 17 463 M
Yield 2019 1,72%
P/E ratio 2019 14,24
P/E ratio 2020 13,22
EV / Sales 2019 1,24x
EV / Sales 2020 1,14x
Capitalization 26 355 M
Chart FRESENIUS
Duration : Period :
Fresenius Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 57,4 €
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
FRESENIUS12.34%28 748
AIER EYE HOSPITAL GROUP CO LTD--.--%12 927
BANGKOK DUSIT MEDICAL SERVICES PCL--.--%12 741
IHH HEALTHCARE BHD--.--%11 573
RAMSAY HEALTH CARE LIMITED24.72%9 884
HAPVIDA PARTICIPACOES E INVESTIMENTOS SA26.19%6 362